


# **Prescribing Basal-Bolus Made Easy**

All commercially insured patients have access to V-Go and V-Go is covered on Medicare Part D

#### **How to Prescribe**

#### **Send Prescriptions to Patients' Preferred Pharmacy**



The majority of V-Go prescriptions are filled by simply sending the prescription to the patients' preferred pharmacy.

\*If V-Go is not covered by your patients' insurance plan and they are commercially insured, a cash pay option is available.

To access V-Go cash pay\* for a patient e-prescribe the V-Go prescription to:

Sterling **Specialty** Pharmacy 1312 Northland Drive, Suite 500 Mendota Heights, MN 55120 NPI: 1225548480 eScribe: 2433693 Phone: 888-618-4126 Fax: 866-588-0371

\*Cash pay is only available for commercially insured patients when V-Go is not covered by their plan.


mannkind



# **Initiating V-Go for Basal-Bolus**

V-Go provides a consistent 24-hour continuous basal infusion and on-demand bolus dosing with meals

#### V-Go is available in 3 dosing options<sup>1</sup>




The Bolus Delivery Button can be clicked 18 times in every 24-hour period. 1 click= 2 units V-Go is applied like a patch and once filled delivers a basal rate of insulin and on-demand bolus dosing.

1. V-Go Instructions for Patient Use. DCN 2560 Rev. C 06/2022. 2. Adapted from Edelman SV, Bode BW, Bailey TS, et al. Insulin pump therapy in patients in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. 3. Data on File. March 2024. MannKind Corporation.

Important Safety Information: If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Wearable Insulin Delivery device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin rritation from the adhesive pad or skin infections at the infusion site. V-Go is magnetic resonance (MR) unsafe and should be removed before having an X-ray, MRI or CT scan.

V-GO, V-GO WEARABLE INSULIN DELIVERY and MANNKIND logo are registered trademarks of MannKind Corporation US-VGO-0134 04/2024 © 2024 MannKind Corporation

### V-Go Dosing Guidance in Patients Switching from MDI\*2,3





<sup>\*</sup>Individual dosing needs may vary